ArticleBMC medicine2026
Comparative outcomes of distal ureterectomy vs. radical nephroureterectomy in high-risk distal ureteral urothelial carcinoma: a two-center cohort study in Northern and Southern China.
Article in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Distal ureterectomy versus radical nephroureterectomy for nonmetastatic distal ureteral urothelial carcinoma: a GRADE-assessed systematic review and meta-analysis of comparative studies.World journal of surgical oncology · 2026Pooled it
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundThis study aimed to compare radical nephroureterectomy (RNU) and distal ureterectomy (DU) in managing high-risk distal ureteral urothelial carcinoma (UC), focusing on renal function, adjuvant chemotherapy (AC), and oncologic outcomes.
methodsA retrospective analysis was conducted on 758 patients initially identified with high-risk distal ureteral cancer treated from 2008 to 2021 at two national centers in Beijing and Guangzhou, China. After selection, 554 patients were included: 371 in the RNU group and 183 in the DU group. Propensity score matching (PSM) was applied, resulting in 176 patients in each group. Primary outcomes included intravesical recurrence-free survival (IVRFS), extravesical recurrence-free survival (EVRFS), overall survival (OS), and cancer-specific survival (CSS). Secondary outcomes assessed associations between eGFR, AC, and survival.
resultsAfter PSM, RNU provided better recurrence control, showing significantly higher IVRFS, particularly in T1/N- and low-grade cases, and in patients with eGFR ≥ 50 mL/min/1.73 m
conclusionsRNU is preferred for early-stage, low-grade cases due to its superior recurrence control, particularly for IVRFS. DU offers comparable outcomes in advanced-stage or high-grade cases, with the added advantage of renal preservation, supporting chemotherapy eligibility. Individualized treatment strategies based on patient-specific factors remain essential for optimizing outcomes in high-risk distal ureteral UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.